Pharma Report 2012: Get Back in Shape

Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

8    GlaxoSmithKline    $14.2B    down 6.6%
Global revenue: $43.4B (7th); down 3.6%

R&D spend: $5.9B (7th), down 3.3%; 13.6% of rev.

Top brands: Advair ($4.6B), Lovaza ($899M), Flovent ($709M), Avodart ($525M), Vesicare ($199M)

Planned launches: Relovair (asthma); 444+719   (COPD); GSK1349572 (HIV/AIDS)

Promotional spend: $1.0B (5th); 7.3% of rev.

Patent expirations: Diskus device (2013-25); Avodart (2015), Lovaza (2017)

Despite three new vaccine approvals and a 12% return on R&D investment, GlaxoSmithKline continues to tread rough waters. The number eight pharmaceutical company has seen vaccine and pharmaceutical sales shrink 31% between 2009 and 2011, partly due to patent expirations. The company exhibits a dogged commitment to plan: despite a US government push to vaccinate boys against HPV, the company said girls and women will remain the target group for vaccine Cervarix, yielding the field to Merck's Gardasil; a generic of top seller Advair could launch soon; and the company has also given ground in the OTC market, including selling 17 brands to Prestige Brand Holdings, although it's having trouble unloading weight-loss drug Alli.

Back to first page

Page 8 of 21
You must be a registered member of MMM to post a comment.

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters